Out With Opioids? Meet the Company Developing Non-Opiate Drugs for Post-Surgical Pain Relief

Photo by Jafar Ahmed on Unsplash

PainReform Ltd. PRFX CEO Ilan Hadar spoke at Benzinga’s All Access: Stocks.

Hadar discussed PainReform’s proprietary therapeutics for non-opiate, post-surgical pain relief as well as the industry’s market size and the company's latest developments.

Watch the Full Interview

https://benzinga.wistia.com/medias/qofvtw7ayf

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.

PRFX Logo
PRFXPainReform Ltd
$2.26-1.74%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
6.72
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...